Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.77 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.77 |
| ▸ | CCR6 | P51684 | 1/20 | 0.77 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | USP7 | Q93009 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83744 | 0.90 | NOS2 (0.62) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL12958280 | 0.88 | NOS2 (0.62) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL27366480 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL7717245 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL144428 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL2582911 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL91617 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL17553226 | 0.87 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL82945 | 0.85 | NOS2 (0.73) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL12447479 | 0.85 | CYP3A4 (0.73) | NOS2MBOAT4CCR6KEAP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9670147-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9556222-B2 | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9102681-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150148384-A1 | A-RING EPOXIDIZED TRITERPENOID-BASED ANTI-INFLAMMATION MODULATORS AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-20140328809-A1 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-11-06 | — | — | US | disclosed |
| US-8455544-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | Reata Pharmaecuticals, Inc. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8440854-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | REATA PHARMACEUTICALS, INC. | 2012-08-30 | — | — | US | disclosed |
| US-8129429-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8124799-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110281955-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885MBOAT4 1458/4885CCR6 2814/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | NOS2 3154/4885MBOAT4 1132/4885CCR6 393/4885 |
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885MBOAT4 415/4885CCR6 2016/4885 |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885MBOAT4 1458/4885CCR6 2814/4885 |
| US-20140328809-A1 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS | BMP2, BMP4, EBP | NOS2 876/4885MBOAT4 2120/4885CCR6 970/4885 |
| US-20110281955-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | TXNRD2, HMOX1, GPX4 | NOS2 83/4885MBOAT4 92/4885CCR6 2296/4885 |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885MBOAT4 415/4885CCR6 2016/4885 |
| US-20150148384-A1 | A-RING EPOXIDIZED TRITERPENOID-BASED ANTI-INFLAMMATION MODULATORS AND METHODS OF USE THEREOF | PTGES, PTGS1, PTGES2 | NOS2 43/4885MBOAT4 881/4885CCR6 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.